Evidence map›Paper›PMID 29748602›Full record

ArticleNature reviews. Cancer2018

Author Correction: Inflammatory breast cancer biology: the tumour microenvironment is key.

Bora Lim, Wendy A Woodward, Xiaoping Wang, James M Reuben, Naoto T Ueno

2 registry-linked trialsAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature reviews. Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02876107 phase2active not recruitingnot on this map

A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2016 to 2027Enrolled42ConditionsBreast Carcinoma, Breast Lump, Edema, ErythemaArmsCarboplatin, Laboratory Biomarker Analysis, Paclitaxel, Panitumumab
NCT03101748 phase1 / phase2terminatednot on this map

A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2018 to 2025Enrolled34ConditionsBreast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7ArmsCyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis, Neratinib, Paclitaxel
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Bora LimDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. blim@mdanderson.org.ORCID http://orcid.org/0000-0002-4182-6058
Wendy A WoodwardMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiaoping WangDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James M ReubenMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naoto T UenoDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. nueno@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The originally published article contained an error in Table 1, in which two neoadjuvant clinical trials (NCT02876107 and NCT03101748) were not included. This omission has been corrected in the online and print versions of the manuscript through the addition of these two trials and their relevant details (agents, cohort details, targeted biology, main targeted pathway or characteristic and phase) to Table 1.

Identifiers

PMID29748602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.